Observation of the Efficacy and Tolerance of Motens® (Lacidipine) in Patients With Essential Hypertension

Observation of the Efficacy and Tolerance of Motens® (Lacidipine) in Patients With Essential Hypertension, Under Normal Conditions Compared With an Open Clinical Trial

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02235415

Enrollment

24526

Registered

2014-09-10

Start date

1998-06-30

Completion date

Unknown

Last updated

2014-09-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension

Brief summary

Study of the efficacy and tolerance of Motens® (lacidipine) in patients with essential hypertension. To obtain information on the dosage used in practice and the tolerance at the start of treatment (12 weeks)

Interventions

DRUGMotens® (lacidipine)

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

Non-hospitalised patients of both sexes aged 18 years or more with essential hypertension requiring treatment according to the recommendations of the German League for Hypertension

Exclusion criteria

Patients who had the contraindications listed in the product information (the case report file contained a copy of the product information)

Design outcomes

Primary

Measure	Time frame
Assessment of efficacy by the investigator on a 4-point verbal rating scale based on changes in blood pressure	Up to 12 weeks after start of drug administration
Assessment of tolerability by investigator on a 4-point verbal rating scale	Up to 12 weeks after start of drug administration
Number of patients with adverse events	Up to 12 weeks after start of drug administration

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026